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Abstract
The prevalence in human cancers of mutations in p53 exemplifies its crucial role as a tumor
suppressor transcription factor. Previous studies have shown that the constitutively active serine/
threonine kinase glycogen synthase kinase-3β (GSK3β) associates with the C-terminal basic domain
of p53 and regulates its actions. In this study we identified the GSK3β N-terminal amino acids 78–
92 as necessary for its association with p53. Inhibitors of GSK3 impaired the acetylation of p53 at
Lys373 and Lys382 near the GSK3β binding region in p53, indicating that GSK3β facilitates p53
acetylation. We also found that acetylation of p53 reduced its association with GSK3β, as well as
with GSK3α. These results indicate that the N-terminal region of GSK3β binds p53, this association
promotes the acetylation of p53, and subsequently acetylated p53 dissociates from GSK3.
Findings
Glycogen synthase kinase-3 (GSK3) phosphorylates more
than 40 substrates, so its actions must be controlled in a
substrate-specific manner to avoid spurious phosphoryla-
tion of unintended substrates upon fluxes in the activity of
GSK3 [1]. This must be accomplished by synchronous reg-
ulation of GSK3 binding to substrates or substrate-con-
taining protein complexes and regulation of GSK3
activity, such as the activity-regulating serine-phosphor-
ylation of GSK3. Thus, the association of GSK3 in protein
complexes is likely as critical as post-translational modifi-
cations in controlling the actions of GSK3. This has been
well-described for the Wnt signaling pathway where GSK3
must be bound to axin to phosphorylate axin-bound β-
catenin [2]. This substrate specificity implies the existence
of different GSK3 recognition motifs for various binding
partners, but GSK3 binding domain studies have been
confined to Wnt signaling proteins [3-5]. Thus, little is
known about binding domains in GSK3, and it is usually
depicted as three domains, a small N-terminal domain, a
slightly larger C-terminal domain, and a predominant
middle kinase domain. Additionally, a nuclear localiza-
tion sequence was recently identified [6].
To understand better the protein-protein interactions of
GSK3β, we investigated the residues required for GSK3β
to bind the tumor suppressor p53 [7]. GSK3β forms a
complex with nuclear p53 to promote p53-induced apop-
tosis, and the C-terminal p53 basic domain is necessary
for this interaction [8-10]. GSK3β also interacts with p53
in the nucleus during cellular senescence [11], and GSK3β
binds p53 in mitochondria [9]. Although the interaction
between GSK3β and p53 has been confirmed in several
studies, the functional consequences are controversial,
possibly because of the many other regulatory influences
on p53 and the context- and cell-specific regulation and
actions of p53. GSK3 has been reported to phosphorylate
Ser33-p53 [12] or Ser315-p53 and Ser376-p53 [13,14],
and to regulate the intracellular localization of p53
[10,13,14]. In this study we identified the domain of
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GSK3β necessary for its association with p53. Further-
more, we found that GSK3 promotes the acetylation of
p53, and that p53 acetylation reduces its association with
GSK3β.
The region of GSK3β that binds to p53 was examined by
expressing mutants of myc-tagged GSK3β fused to a
nuclear localization sequence (NLS) in p53-null H1299
cells that inducibly express wild-type HA-tagged p53.
Immunostaining of transfected cells demonstrated that all
GSK3β constructs were expressed in the nucleus (Figure 1
and data not shown). Following expression of NLS-
GSK3β constructs, the expression of HA-p53 was induced,
and co-immunoprecipitation of p53 with GSK3β con-
structs was measured. GSK3β was sequentially truncated
from the C-terminal to the smallest construct consisting of
residues 1–134, and each of these GSK3β constructs asso-
ciated with p53 (Figure 2A), indicating that the N-termi-
Nuclear localization of expressed GSK3β constructs Figure 1
Nuclear localization of expressed GSK3β constructs. p53-null human lung carcinoma H1299 cells that express inducible 
wild-type HA-tagged p53 were transiently transfected with wild-type GSK3β-NLS-myc (1–420) or the indicated mutants of 
GSK3β-NLS-myc. Constructs generated by ligating rat GSK3β cDNA into the pShooter vector pCMV/myc/nuc (Invitrogen) 
were expressed using FuGENE 6 (Roche). NLS-myc vector (myc) was used as a negative control. After 24 hr, expression was 
examined by immunoblotting and immunostaining with anti-myc-tag (Cell Signaling) and Alexa Fluor 488 goat anti-mouse IgG 
(Invitrogen). Nuclei were labeled with 1 μg/ml bisbenzimide (Bis; blue). The expression level of each mutant construct was sim-
ilar to wild-type GSK3β-NLS-myc and all GSK3β-NLS-myc constructs (green) were expressed in the nucleus. 100× magnifica-
tion.
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Identification of the GSK3β domain required for association with p53 Figure 2
Identification of the GSK3β domain required for association with p53. Schematic diagrams (left) depict GSK3β con-
structs (A) sequentially truncated from the C-terminal, (B) sequentially truncated from the N-terminal, and (C) deletion con-
structs. GSK3β constructs were transiently transfected into H1299 cells and HA-p53 was inducibly expressed by removing 
doxycycline from the medium for 24 hr [9]. Cells were subjected to lysis, immunoprecipitation using sheep anti-mouse IgG 
Dynabeads (Dynal Biotech) and 1 μg anti-HA (Covance) and immunoblotting as indicated. The heavy chain (HC) and light chain 
(LC) of IgG are indicated, and β-actin was used as loading control.
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nal amino acids 1–134 of GSK3β are required for binding
to p53. Subsequently, smaller 25-residue N-terminal
sequential truncations of GSK3β were expressed and these
showed that deletion of the N-terminal 77 residues did
not abrogate binding to p53, but deletion of the N-termi-
nal 92 or 114 residues eliminated association with p53
(Figure 2B). This demonstrates that a region encompass-
ing residues 78–92 of GSK3β was necessary for p53 bind-
ing. This localization was confirmed by constructing three
different deletion mutants of GSK3β with this region
eliminated, which failed to bind p53 (Figure 2C).
Residues 78–92 of GSK3β that are required for association
with p53 reside close to the N-terminus of GSK3β within
the β-strand (Figure 3A). This region of GSK3β required
for association with p53 is composed of two externally
exposed loops that might be easily assessable to binding
partners and contains K85/K86 that are critical for GSK3β
kinase activity. Thus, we tested if GSK3β activity is
required for its association with p53. Kinase dead GSK3β
was generated by mutating K85 and K86 to alanine, with
an NLS and myc-tag (K85A/K86A-NLS-GSK3β). Co-
immunoprecipitation showed that both wild-type and
kinase-dead GSK3β associate with p53, demonstrating
Diagram of the GSK3β region required for association with p53 Figure 3
Diagram of the GSK3β region required for association with p53. (A) The sequence of GSK3β shows the region 
required for association with p53, consisting of amino acids 78–92, that is located close to the N-terminus of GSK3β. The 
molecular rendering of a monomer of GSK3β was generated using the Cn3D software from the NCBI based on the protein 
data bank file 1O9U http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml, and the p53 binding domain of GSK3β was 
depicted as yellow. (B) H1299 cells were transiently transfected to express wild-type GSK3β-NLS-myc (1–420 amino acids; 
WT) or kinase-dead GSK3β-NLS-myc (K85A/K86A), and HA-p53 was inducibly expressed, for 24 hr. Cells were subjected to 
lysis and anti-HA was used to immunoprecipitate p53, followed by immunoblotting with anti-myc antibody to detect GSK3β-
NLS-myc. The levels of expressed HA-p53, NLS-myc-GSK3β, and β-actin were determined by immunoblotting.
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that GSK3β activity is not required for association with
p53 (Figure 3B).
We examined if GSK3 regulates p53 acetylation because
GSK3β binds p53 C-terminal 364–373 residues [9] con-
taining three sites of p53 acetylation (K370, K372, K373)
and very close to two other acetylation sites (K381, K382).
Previously, the coactivators p300 and PCAF were shown
to acetylate the C-terminus region of p53, which activates
the DNA binding activity of p53 [15,16]. In addition to
this role, the acetylation of p53 contributes to regulating
its stability, transcriptional activity, and localization [17-
19]. Trichostatin A (TSA) is a well-established inhibitor of
histone deacetylases (HDACs) in classes I, II, and IV, com-
prising HDAC 1–11, and nicotinamide inhibits HDAC
class III, comprising Sirt1-7 [20]. Therefore, SH-SY5Y cells
were treated with 1 μM camptothecin for 3 hr to increase
p53 levels, with or without 1 μM TSA plus 5 mM nicotina-
mide to inhibit p53 deacetylation. p53 levels were
increased by camptothecin treatment and co-treatment
with TSA/nicotinamide increased p53 acetylation at K373
and K382, but not at K320 (Figure 4A). Treatment with
three structurally diverse GSK3 inhibitors, lithium,
SB216763, and CHIR99021, significantly inhibited the
acetylation of p53 at K373 and K382 (Figure 4B). In con-
trast, lithium and SB216763 did not inhibit p53 K320
acetylation (99 ± 5% and 140 ± 15%, respectively). These
results implicate GSK3 as a modulator of p53 acetylation,
indicating that GSK3 promotes p53 acetylation.
We investigated if acetylation of p53 regulates its associa-
tion with GSK3 since p53 acetylation sites are within, or
close to, the residues of p53 required for its association
with GSK3. SH-SY5Y cells were treated with 1 μM camp-
tothecin for 3 hr to increase p53 levels, in the absence or
presence of 1 μM TSA plus 5 mM nicotinamide to inhibit
the deacetylation of p53. Each isoform of GSK3 was
immunoprecipitated and p53 was found to co-immuno-
precipitate with both GSK3 isoforms. Inclusion of TSA/
nicotinamide with camptothecin treatment increased p53
acetylation on K373 and K382 but not on K320, and there
was a large inhibition of the association of p53 with both
GSK3 isoforms compared with their association with p53
in the absence of TSA/nicotinamide (Figure 4C). These
results indicate that acetylation of p53 at K373 and K382,
proximal to the GSK3β binding region, inhibits the asso-
ciation of GSK3 with p53.
p53 and GSK3 each has critical roles in determining cell
survival [1,7]. Therefore, it is particularly interesting to
determine mechanisms regulating interactions between
the two proteins. In this study we identified a novel pro-
tein-interacting region near the N-terminus of GSK3 that
is critical for its interaction with p53. Furthermore, we
found that GSK3 promotes the acetylation of p53 at sites
(K373 and K382) near the GSK3β-binding region of p53,
which spans residues 364–373. Highly acetylated p53, in
turn only poorly associates with GSK3. These findings
indicate that a region near the N-terminus of GSK3 asso-
ciates with the C-terminal basic domain of p53 that con-
tains several sites that can be acetylated, GSK3 promotes
the acetylation of p53, and acetylated p53 dissociates
from GSK3.
Little is known about domains in GSK3 that are critical for
its interactions with other proteins despite the importance
of these interactions for controlling and directing the
actions of GSK3 [1]. Since the interaction between GSK3β
and p53 is important for controlling the actions of both
proteins [8], we examined regions in GSK3 that are
required for this interaction. Previously overlapping but
non-identical binding sites in the carboxy lobe of GSK3β
were identified as critical for associating with proteins in
the Wnt signaling pathway, axin and GBP/FRAT [3-5].
Both axin and GBP bind a channel in GSK3β formed by
an α-helix (residues 262–273) and an extended loop (res-
idues 285–299), so their binding is mutually exclusive,
but the interacting residues of GSK3β differ for axin and
GBP [2]. Unlike the Wnt signaling proteins, this entire C-
terminal region of GSK3 was completely dispensable for
its interaction with p53, which required GSK3β residues
78–92. Although the binding domain contains residues
K85/K86 that are necessary for its kinase activity, kinase-
dead GSK3β with these residues mutated to alanine asso-
ciated with p53 equivalently to wild-type GSK3β indicat-
ing that GSK3β activity does not affect the interaction with
p53, which has also been shown for kinase-dead GSK3β
binding to components of the Wnt signaling system [21].
Thus, these results demonstrate that different domains of
GSK3β are utilized to enable GSK3β to regulate the Wnt
and p53 systems. Differential protein-associating
domains of GSK3β likely contribute to enabling GSK3 to
selectively regulate phosphorylation of its substrates,
which number over forty.
Several effects of GSK3 on p53 have been reported,
including facilitation of its transcriptional activity and
apoptosis [8-10], p53 phosphorylation [12-14], and p53
intracellular localization and trafficking [22]. Since the
region encompassing residues 364–373 in the C-terminal
basic domain of p53 that is required for its association
with GSK3β contains several sites that can be acetylated,
we examined if GSK3 regulates p53 acetylation and if p53
acetylation regulates its association with GSK3. Both of
these were found to occur, as GSK3 inhibitors substan-
tially reduced the acetylation of p53 at two sites near the
region of p53 required for its association with GSK3β, res-
idues K373 and K382, but not at a more distant acetyla-
tion site, K320, and increased acetylation of p53
decreased its association with GSK3. Although the func-Molecular Cancer 2009, 8:14 http://www.molecular-cancer.com/content/8/1/14
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Figure 4 (see legend on next page)
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tional roles of p53 acetylation remain controversial, sev-
eral reports suggest that acetylation increases p53 stability
and promotes co-activator recruitment, leading to tran-
scriptional activation of target genes [23]. Our findings
indicate that the N-terminal region of GSK3 associates
with the basic domain of p53 and this facilitates p53
acetylation which leads to dissociation of p53 from GSK3.
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GSK3 regulates p53 acetylation which regulates association with GSK3β Figure 4 (see previous page)
GSK3 regulates p53 acetylation which regulates association with GSK3β. (A) SH-SY5Y cells were preincubated with 
1 μM TSA and 5 mM nicotinamide (T/N) for 2 hr and treated with 1 μM camptothecin (CA) for 3 hr. Total p53 was immuno-
precipitated followed by immunoblotting with antibodies specific for acetylated Lys373 (Ac-K373-p53), Lys382 (Ac-K382-p53), 
Lys320 (Ac-K320-p53) (Trevigen), total p53 (Santa Cruz), and β-actin (Sigma). (B) Quantitative analysis of the percentage of 
acetylated p53. SH-SY5Y cells were preincubated with 1 μM TSA and 5 mM nicotinamide for 2 hr, with GSK3 inhibitors, 20 
mM lithium (Li), 10 μM SB216763 (SB), or 10 μM CHIR99021 (CHIR), for 30 min, and treated with 1 μM camptothecin for 3 
hr. Quantitative values are means ± S.E.; n = 3. *p < 0.05, ANOVA with Dunnett's post hoc multiple comparisons test. (C) SH-
SY5Y cells were preincubated with 1 μM TSA and 5 mM nicotinamide (T/N) for 2 hr and treated with 1 μM camptothecin (CA) 
for 3 hr. The association of GSK3α/β with p53 was assessed by immunoprecipitation of GSK3α or GSK3β followed by immu-
noblotting total p53. The endogenous total p53, total GSK3α/β, acetylated p53 (Ac-K373-p53, Ac-K382-p53, Ac-K320-p53), 
and β-actin levels were determined by immunoblotting.